Cloud-Clone launches triple-validated XIAP antibody for apoptosis research

Cloud-Clone Corp. introduced a XIAP antibody validated for Western Blot, IHC and IF to support researchers studying apoptosis, tumor resistance and inflammatory disease. The product is aimed at labs that need one reagent to deliver consistent results across multiple workflows.

Why it matters: - XIAP is a key apoptosis regulator tied to tumor progression, drug resistance and inflammatory disease research. - A single antibody that works across Western Blot, IHC and IF can reduce sample use, lower costs and improve reproducibility in multi-step studies. - Better detection tools matter because XIAP is used in basic biology, translational cancer work and therapeutic target discovery.

What happened: - Cloud-Clone Corp. released a validated XIAP antibody, product ID PAC606Hu01. - The antibody is validated for Western Blot, Immunohistochemistry and Immunofluorescence. - The launch is positioned for researchers studying apoptosis regulation, tumor resistance and related therapeutic targets.

The details: - Western Blot testing showed specific bands at the expected molecular weight in HepG2, 293T, Jurkat and Hela cell lysates. - Western Blot testing also showed usable detection in porcine liver and porcine heart lysates, indicating cross-species reactivity. - IHC testing produced robust staining with low background in human kidney tissue and human breast cancer tissue sections. - IF testing showed clear green fluorescent XIAP signal in MCF7 cells. - The IF results showed contrast between cytoplasm and nuclear compartments, supporting subcellular localization studies. - The antibody is rabbit-derived and polyclonal, which allows recognition of multiple epitopes on XIAP. - Cloud-Clone says the antibody can be customized with Biotin, HRP and different fluorophores. - Cloud-Clone says its products have been cited in more than 42,000 SCI publications worldwide. - The company says it has nearly 20 years of experience in immunoassay development.

Between the lines: - XIAP research is moving beyond apoptosis alone, with applications in chemotherapy sensitization, radiotherapy sensitization, immunotherapy combinations and inflammation studies. - The release addresses a common lab problem: antibodies that perform well in one assay but fail in others. - Multi-application validation is becoming more important as researchers compare protein expression, tissue location and intracellular distribution in the same project.

What's next: - Researchers can visit the official Cloud-Clone website or contact authorized regional distributors for product specifications and technical support. - Cloud-Clone is likely to position the antibody for ongoing preclinical and basic research as XIAP studies expand across oncology and inflammatory disease. - The company continues to offer related research tools, including proteins, antibodies, ELISA kits, primary cells and multiplex cytokine assay kits.

The bottom line: - Cloud-Clone is betting that a triple-validated XIAP antibody will save time and improve confidence in apoptosis-focused research.